Douglas Bennett, DO
Infectious Disease · Westfield, NJNPI 1710903497
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 333 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Gilead at 43.6% of the total.
Across 333 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- Viiv Healthcare Company$1K
- Novo Nordisk$511
- Merck$409
- Tactile Systems Technology Inc$366
- Theratechnologies Inc.$236
- plus $974 from 23 others
What the payments were for
- Food & beverage$6,699100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 126 | $2,925 |
| Viiv Healthcare Company | 77 | $1,290 |
| Novo Nordisk | 33 | $511 |
| Merck | 23 | $409 |
| Tactile Systems Technology Inc | 9 | $366 |
| Theratechnologies Inc. | 7 | $236 |
| AbbVie(2 entities) | 10 | $151 |
| Johnson & Johnson | 7 | $105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $83 |
| Lilly USA, LLC | 5 | $73 |
| Bioventus LLC | 2 | $66 |
| Amarin Pharma, Inc. | 4 | $55 |
| Xeris Pharmaceuticals, Inc. | 3 | $50 |
| EMD Serono, Inc. | 3 | $47 |
| Cequr Corporation | 2 | $44 |
| Abbott | 2 | $41 |
| BD | 2 | $34 |
| Mannkind Corporation | 2 | $31 |
| Medtronic | 1 | $26 |
| Insulet Corporation | 1 | $23 |
| Kerecis Limited | 1 | $19 |
| Alvogen Inc | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Embecta Corp. | 1 | $15 |
| Sequel Med Tech, LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$446
- DOVATO$211
- Descovy$123
- Epclusa$122
- Flexitouch Plus$112
- Entre Plus$112
- Yeztugo$109
How this compares
$6,711 in reported general payments places this provider in the 85th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 413 | $1,793,931 |
| DovatoDolutegravir Sodium/Lamivudine | 189 | $626,474 |
| TivicayDolutegravir Sodium | 48 | $184,799 |
| JulucaDolutegravir/Rilpivirine | 40 | $134,669 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 18 | $93,808 |
| PrezcobixDarunavir/Cobicistat | 16 | $39,786 |
| Darunavir | 27 | $35,835 |
| PifeltroDoravirine | 14 | $27,343 |
| EdurantRilpivirine Hcl | 12 | $17,149 |
| Ritonavir | 13 | $8,082 |
| ValacyclovirValacyclovir Hcl | 20 | $935 |
| Cefadroxil | 46 | $798 |
| Nystatin | 15 | $573 |
| Rosuvastatin Calcium | 23 | $521 |
| Atorvastatin Calcium | 32 | $373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $2,925 | $1,793,931413 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Juluca | $1,290 | $945,942277 claims |
| Johnson & JohnsonPrezcobix | $105 | $39,78616 claims |
| MerckPifeltro | $409 | $27,34314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 334 infectious disease providers in New Jersey.
Other infectious disease in Westfield
- Keith GottesdienerRahway$2.1M
- Jihad SlimNewark$2.1M
- Maria SzabelaNewark$474K
- Ronald NahassHillsborough$213K
- Christopher LucastiSomers Point$112K
- Spartaco BellomoJersey City$111K
- Jack BoghossianBayonne$97K
- Adriana GrigoriuJersey City$89K
- Sukrut DwivediOakhurst$75K
- Bindu BalaniHackensack$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.